VERDE SCIENCE R&D TEAM READY TO MOVE FORWARD WITH DESIGN OF
RESEARCH PLAN
Richmond, BC - November 04, 2014 - (OTCPK:
VRCI) Verde Science, Inc., a Medical Research and Development
Company, is pleased to announce that it has assembled its complete
Research and Development team under the direction of its newly
appointed Chief Technology Officer, Manit Patel, and it has
initiated the coordinated design of its overarching R&D plan.
The recently completed team includes:
- Manit Patel, CTO -- B.Sc. in Pharmaceutical Science from the
Institute of Chemical Technology of Mumbai, India. MBA from
Queensland University of Technology in Brisbane, Australia.
Expertise in pharmaceutical research, product design, production,
and business strategy and development, with a broad network of
international business contacts. He has successfully launched
9 products for Sterkem during his tenure.
- Drs. Ratnesh Jain and Prajatka Dandekar Jain, Senior
Researchers – Dr. Prajakta Jain has a Ph.D. in Bioprocess
Technology with expertise in extraction and isolation of active
ingredients from plants. Dr. Ratnesh Jain has a Ph.D. in
nanocarriers and drug delivery systems. Both researchers are
faculty at the Institute of Chemical Technology and will be pivotal
to cost effective extraction, isolation and formulation design from
the marijuana plant.
- The Institute of Chemical Technology – The ICT and Verde
Science are moving toward an alliance that will offer expanded
research capabilities for Verde’s ongoing scientific inquiries that
will utilize faculty and graduate students to supplement Verde’s
internal scientists.
- Sterkem Group – Verde Science and Sterkem Group
(www.sterkempharma.com) a Mumbai, India based pharmaceutical
research, production and marketing firm, are finalizing the plan
for a pharmaceutical development venture that will refine the
resultant cannabis-based extracts for specific medical conditions
identified by Verde’s R&D program into deliverable and
marketable pharmaceutical formulations.
“We are immediately beginning the coordinated design of our
overall R&D program with our front end and back end team
members in India, so that all members of the team will be
constantly in the feedback loop throughout the R&D process for
each compound we are studying”, according to Manit Patel.
“This approach along with our synergistic and highly skilled team
will streamline our processes and yield optimal results, without
having to wait for a R&D license in Canada”, concluded Mr.
Patel.
The Verde Science approach is a pharmacological/medical study of
cannabis extracts that actually have an effect on specific medical
conditions, while minimizing any deleterious effects of smoking
medical marijuana or inhaling vapors that have diminished its use
in mainstream medicine. The company’s scientists have already
identified certain cannabis extracts they believe show distinct
promise for further study. Research will begin in India where
marijuana research is far less regulated, costs are lower and
traditional Indian medicine has been advocating the use of
marijuana to treat certain medical conditions for centuries.
This expedited and low cost scientific approach sets Verde Science
apart from most in the medical marijuana space, as the company has
no intention to become a licensed marijuana grower/operator in
Canada or the United States, nor does it intend to apply for a MMPR
license with Health Canada. Verde Science is discussing possible
collaborations with private companies that have applied for a
Medical Marijuana R&D only license from Health Canada and are
awaiting final approvals. The process and requirements to
receive a R&D license can be found on the Health Canada Website
( www.hc-sc.gc.ca) (http://www.hc-sc.gc.ca/hc-ps/substancontrol/exemptions/applic-scien-eng.php)
(Some of the statements in this paragraph are clarifying statements
made at the request of the British Columbia Securities
Commission.)
About Verde Science, Inc. (VRCI)
Verde Science, Inc. (www.VerdeScienceInc.com) is a
public company trading under the symbol OTCPK:
VRCI. The Company is focused on Medical Research and
Development, which includes Medical Marijuana Research and
Development.
Safe Harbor Statements?Certain information contained in this
news release constitutes "forward-looking statements" as such term
is used in applicable United States and Canadian laws. Generally,
these forward-looking statements can be identified by the use of
forward-looking terminology such as "expects" or "does not expect",
"is expected", "anticipates" or "does not anticipate", "plans",
"estimates", "intends" or "believes", or that certain actions,
events or results "may", "could", "would", "might" or "will be
taken", "occur", or "be achieved". Forward-looking statements
are based on the opinions and estimates of management as of the
date such statements are made, and are subject to known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements. Many of these factors are beyond the
Company's ability to control or predict. Important factors that may
cause actual results to differ materially and that could impact the
Company and the statements contained in this news release can be
found in the Company's filings with the SEC. Such risks and other
factors include, among others, the ability to locate and acquire
suitable interests in alternative medicine manufacturing operations
on terms acceptable to the Company, the availability of financing
on acceptable terms, accidents, labor disputes, acts of God and
other risks of the alternative medicine industry including, without
limitation, delays in obtaining governmental approvals or permits,
title disputes or claims limitations on insurance coverage. The
Company believes that the expectations reflected in the
forward-looking statements included in this news release are
reasonable; however, no assurance can be given that these
expectations will prove to be correct, and such forward-looking
statements should not be unduly relied upon. The Company assumes no
obligation to update or supplement any forward-looking statements
whether as a result of new information, future events or
otherwise.
For further information please see our investor profile available
on our website (www.verdescienceinc.com) or
contact:
Harp Sangha, Chairman/CEO
1-858-210-0236
harpsangha@shaw.ca
Louis Silver, Director of Investor Relations
610-710-1303
lsilver@verdescienceinc.com